Table 3.
Vessel median diameter as a prognostic factor in multivariable analysis of the “TMA” cohort in ER+ breast cancer subset
| Variables | Multivariable analysis | |
|---|---|---|
| HR (95% CI) | p value | |
| Vessel median diameter | ||
| Low | 1 (reference) | |
| High | 2.66 (1.28–5.53) | 0.009 |
| Age at diagnose | ||
| ≤ 60 | 1 (reference) | |
| > 60 | 1.8 (0.9–3.59) | 0.095 |
| Tumor size | ||
| ≤ 20 mm | 1 (reference) | |
| > 20 mm | 1.92 (0.86–4.26) | 0.111 |
| Histologic grade | ||
| Grade 1 | 1 (reference) | |
| Grade 2 | 1.39 (0.64–2.998) | 0.41 |
| Grade 3 | 2.65 (1.00–7.02) | 0.05 |
| Lymph node status | ||
| N0 | 1 (reference) | |
| N1 | 3.78 (1.79–7.99) | 0.001 |
| Progesterone receptor status | ||
| + | 1 (reference) | |
| − | 1.93 (0.86–4.36) | 0.112 |
| HER2 status | ||
| − | 1 (reference) | |
| + | 0.98 (0.35–2.71) | 0.962 |
The 267 ER+ breast cancer cases of the “TMA” cohort were included in the regression model. Vessel median size variable was dichotomized as “low (0–50%)” and “high (>50%)” group based on the median value
p value are calculated based on Wald test; HR is based on cause-specific Cox-regression model
HR hazard ratio, CI confidence interval, TMA tissue microarray, HER2 human epidermal growth factor 2, ER estrogen receptor, PR progesterone receptor